TW202332473A - 放射性核種複合物的組合療法 - Google Patents
放射性核種複合物的組合療法 Download PDFInfo
- Publication number
- TW202332473A TW202332473A TW111140975A TW111140975A TW202332473A TW 202332473 A TW202332473 A TW 202332473A TW 111140975 A TW111140975 A TW 111140975A TW 111140975 A TW111140975 A TW 111140975A TW 202332473 A TW202332473 A TW 202332473A
- Authority
- TW
- Taiwan
- Prior art keywords
- dota
- weeks
- day
- dose
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163272447P | 2021-10-27 | 2021-10-27 | |
| US63/272,447 | 2021-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202332473A true TW202332473A (zh) | 2023-08-16 |
Family
ID=84365353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111140975A TW202332473A (zh) | 2021-10-27 | 2022-10-27 | 放射性核種複合物的組合療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250387523A1 (enExample) |
| EP (1) | EP4422701A1 (enExample) |
| JP (1) | JP2024539952A (enExample) |
| KR (1) | KR20240093832A (enExample) |
| CN (1) | CN118159304A (enExample) |
| AU (1) | AU2022374887A1 (enExample) |
| CA (1) | CA3234495A1 (enExample) |
| IL (1) | IL312106A (enExample) |
| MX (1) | MX2024004961A (enExample) |
| TW (1) | TW202332473A (enExample) |
| WO (1) | WO2023073603A1 (enExample) |
-
2022
- 2022-10-27 CA CA3234495A patent/CA3234495A1/en active Pending
- 2022-10-27 KR KR1020247016801A patent/KR20240093832A/ko active Pending
- 2022-10-27 CN CN202280069041.9A patent/CN118159304A/zh active Pending
- 2022-10-27 EP EP22814157.8A patent/EP4422701A1/en active Pending
- 2022-10-27 WO PCT/IB2022/060331 patent/WO2023073603A1/en not_active Ceased
- 2022-10-27 IL IL312106A patent/IL312106A/en unknown
- 2022-10-27 AU AU2022374887A patent/AU2022374887A1/en active Pending
- 2022-10-27 US US18/704,804 patent/US20250387523A1/en active Pending
- 2022-10-27 TW TW111140975A patent/TW202332473A/zh unknown
- 2022-10-27 MX MX2024004961A patent/MX2024004961A/es unknown
- 2022-10-27 JP JP2024524610A patent/JP2024539952A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250387523A1 (en) | 2025-12-25 |
| CA3234495A1 (en) | 2023-05-04 |
| CN118159304A (zh) | 2024-06-07 |
| WO2023073603A1 (en) | 2023-05-04 |
| AU2022374887A1 (en) | 2024-04-11 |
| MX2024004961A (es) | 2024-05-08 |
| JP2024539952A (ja) | 2024-10-31 |
| IL312106A (en) | 2024-06-01 |
| EP4422701A1 (en) | 2024-09-04 |
| KR20240093832A (ko) | 2024-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7839135B2 (ja) | 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法(trt)の使用 | |
| JP2024541595A (ja) | 放射線医薬的治療方法及び使用 | |
| Chen et al. | Development of [177Lu] Lu-LNC1010 for peptide receptor radionuclide therapy of nasopharyngeal carcinoma | |
| CN119095629A (zh) | 用于癌症患者的诊断方法 | |
| JP2026505341A (ja) | 神経膠芽腫を治療するための方法 | |
| WO2024176147A1 (en) | Methods for treating breast cancer | |
| US20240050597A1 (en) | Radiolabelled alpha-v beta-3 and/or alpha-v beta-5 integrins antagonist for use as theragnostic agent | |
| Nedelcovych et al. | JHU-2545 selectively shields salivary glands and kidneys during PSMA-targeted radiotherapy | |
| US20250387523A1 (en) | Combination therapy of radionuclide complex | |
| WO2010117992A2 (en) | Coupled identification and treatment of cancer | |
| US20240042067A1 (en) | [177lu] lutetium-psma i&t composition, kit, method of making, and method of using thereof | |
| KR20250109190A (ko) | 암의 식별 및/또는 치료 | |
| WO2025126151A1 (en) | Methods for treating breast cancer | |
| KR20260014588A (ko) | 전립선암의 진단 및/또는 치료 방법 |